FDA panel backs Novartis psoriasis drug secukinumab
This article was originally published in Scrip
Executive Summary
Novartis gained the unanimous backing from the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) on 20 October for the firm's experimental psoriasis drug secukinumab.